MedPath
Found 43 clinical trials|View Analysis
Sort by:

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Phase 2
Recruiting
Conditions
EGFR
Non-Small Cell Lung Cancer
Locally Advanced Non-Small Cell Lung Cancer
Pemetrexed
Carboplatin
Bevacizumab
Antineoplastic Agents
Tyrosine Kinase Inhibitor
Interventions
First Posted Date
2025-01-01
Last Posted Date
2025-01-06
Lead Sponsor
Peng Zhang
Target Recruit Count
60
Registration Number
NCT06755684
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Vorolanib in the Second-line Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma

Recruiting
Conditions
Neoplasms
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Female Urogenital Diseases
Male Urogenital Diseases
Urogenital Diseases
Kidney Diseases
Urologic Diseases
Carcinoma
First Posted Date
2024-11-06
Last Posted Date
2024-11-06
Lead Sponsor
Jinling Hospital, China
Target Recruit Count
39
Registration Number
NCT06676527
Locations
🇨🇳

Jinling Hospital, Nanjing, Jiangsu, China

A Retrospective Study in Patients with Liver Injury After the Use of Novel Antineoplastic Agents

Recruiting
Conditions
Liver Injury
Liver Injury, Drug-Induced
First Posted Date
2024-11-01
Last Posted Date
2024-11-01
Lead Sponsor
Drug Induced Liver Disease Study Group
Target Recruit Count
2000
Registration Number
NCT06670391
Locations
🇨🇳

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB

Not Applicable
Not yet recruiting
Conditions
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Myocardial Ischemia
Atherosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Immunosuppressive Agents
P2Y12 Inhibitor
Coronary Artery Disease
Interventions
Device: Drug-coated balloon
Drug: Single antiplatelet therapy (SAPT)
Drug: Dual antiplatelet therapy (DAPT)
First Posted Date
2024-08-02
Last Posted Date
2024-08-14
Lead Sponsor
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Target Recruit Count
416
Registration Number
NCT06535568

A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: HRS-4642
First Posted Date
2024-07-25
Last Posted Date
2024-07-25
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
118
Registration Number
NCT06520488
Locations
🇨🇳

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

Not yet recruiting
Conditions
Cardiac Diseases
Cancer
Vascular Diseases
Cardiovascular Diseases
Interventions
Drug: Antineoplastic Agents
First Posted Date
2024-05-10
Last Posted Date
2024-05-10
Lead Sponsor
The First Affiliated Hospital of Xinxiang Medical College
Target Recruit Count
800000
Registration Number
NCT06409481

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Phase 2
Not yet recruiting
Conditions
Carcinoma
Gallbladder Cancer
Angiogenesis Inhibitors
Tislelizumab
Antineoplastic Agents, Immunological
Immunotherapy
Intrahepatic Cholangiocarcinoma
Surufatinib
Interventions
First Posted Date
2023-11-18
Last Posted Date
2023-11-18
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
41
Registration Number
NCT06134193

Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC

Phase 2
Recruiting
Conditions
Neoplasms
Urologic Neoplasms
Kidney Neoplasms
Female Urogenital Diseases
Urologic Diseases
Male Urogenital Diseases
Carcinoma
Carcinoma, Renal Cell
Antineoplastic Agents
Urogenital Neoplasms
Interventions
First Posted Date
2023-11-02
Last Posted Date
2024-04-26
Lead Sponsor
Jinling Hospital, China
Target Recruit Count
32
Registration Number
NCT06114940
Locations
🇨🇳

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, Nanjing, Jiangsu, China

Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma

Phase 2
Recruiting
Conditions
Neoplasms
Carcinoma, Squamous
Antineoplastic Agents
Interventions
First Posted Date
2023-07-27
Last Posted Date
2024-05-21
Lead Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Target Recruit Count
25
Registration Number
NCT05964101
Locations
🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Not Applicable
Recruiting
Conditions
Breast Neoplasms
Neoplasms, Breast
Antineoplastic Agents
ESR1 Gene Mutation
Breast Diseases
Hormone Receptor Positive Breast Carcinoma
Aromatase Inhibitors
Interventions
Diagnostic Test: Liquid biopsy and CT scan
First Posted Date
2023-04-14
Last Posted Date
2023-04-14
Lead Sponsor
Centro di Riferimento Oncologico - Aviano
Target Recruit Count
164
Registration Number
NCT05814224
Locations
🇮🇹

Asst Papa Giovanni Xxiii- Bergamo, Bergame, Bergamo, Italy

🇮🇹

Centro di Riferimento Oncologico - Aviano, Aviano, Pordenone, Italy

🇮🇹

Asst Ospedali Civili Di Brescia, Brescia, Italy

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath